Clinical Significance of Cystatin-C in Patients with Multiple Myeloma_West China Medical Journal

Authors：

XIAO Rong

Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, P. R. China;

Corresponding author：

Keywords：

多发性骨髓瘤; 血清胱抑素C; 肾功能损害; 肿瘤负荷; 溶骨性损害

DOI：

CNKI: 51-1356/R.20120214.1338.002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　测定多发性骨髓瘤（MM）患者血清胱抑素C （Cys-C）的水平，探讨Cys-C与国际分期体系（ISS）、血β2-微球蛋白、溶骨性损害等指标的关系。方法　收集2008年1月－2010年9月32例初治和8例复发的MM患者作为研究对象，同时收集40例健康体检者的检查资料作为对照组，测定血清Cys-C、血肌酐（Scr）、血β2-微球蛋白。采用核素全身骨显像（ECT）观察患者的溶骨性病变部位数。结果　患者血清Cys-C水平（1.40 mg/L）明显高于健康对照组（0.90 mg/L）（P＜0.01）；在MM患者中Cys-C比Scr更敏感，能反映肾小球滤过率；血清Cys-C水平与ISS分期晚，血β2-微球蛋白升高以及溶骨性病变进展密切相关。结论　 MM患者的Cys-C水平高于健康者。Cys-C是骨髓瘤肾损害的早期敏感标志物，与肿瘤负荷及溶骨性损害密切相关，可作为评价肿瘤负荷的潜在指标。
Objective To evaluate the serum levels of cystatin-C in patients with multiple myeloma (MM), and to explore its possible correlations with clinical data, including ISS stage, serum β2-microglobulin, and advanced lytic lesions. Methods 　From January 2008 to September 2010, serum cystatin-C, creatinine (Scr), and β2-microglobulin in 32 patients with MM, 8 patients with relapsed disease, and in 40 healthy controls were detected by automatic biochemistry analyzer detection. According to skeleton ECT, grading of osteolytic lesion was observed. Results 　The levels of serum cystatin-C of patients with MM were significantly higher than those of the controls. Serum cystatin-C could reflect the glomerular filtration rate , and was more sensitive than Scr in patients with renal lesion. Serum cystatin-C had ber correlations with advanced ISS stages, high levels of serum β2-microglobulin, and extensive bone diseases. Conclusion 　Serum cystatin-C is a sensitive marker of renal lesion in patients with MM, it could be a potential indicator to assess the tumor burden.

Citation： XIAO Rong. Clinical Significance of Cystatin-C in Patients with Multiple Myeloma. West China Medical Journal, 2012, 27(2): 171-173. doi: CNKI: 51-1356/R.20120214.1338.002 Copy

1.	Abbott KC, Agodoal LY. Multiple myeloma and light chain associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival[J]. Clin Nephrol, 2001, 56(3): 207 -210.
2.	Lamb EJ, Stowe HJ, Simpson DE, et al. Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful[J]. Clin Chem, 2004, 50(10): 1848-1851.
3.	Heidtmann HH, Salge U, Abrahamson M, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines[J]. Clin Exp Metastasis, 1997, 15(4): 368-381.
4.	Kos J, Stabuc B, Cimerman N, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression[J]. Clin Chem, 1998, 44(11): 2256-2257.
5.	De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays[J]. Oncogene, 2002, 21(44): 6848-6857.
6.	张之南, 沈悌. 血液病诊断及疗效标准[M]. 2版. 北京: 科学出版社，1998: 168-373.
7.	Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int, 2004, 66(3): 1115-1122.
8.	Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: esults of a 4-year follow-up study[J]. J Am Soc Nephrol, 2005, 16(5):1404-1412.
9.	Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD[J]. Am J Kidney Dis, 2008, 51(3): 395-406.
10.	Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma[J]. Bone Marrow Transplant，2007, 39(10): 605-611.
11.	Eleutherakis-Papaiakovou V, Bamia A, Gika D, et al. Renal failure in multiple myeloma: incidence correlations, and prognostic significance[J]. Leuk Lymphoma, 2007, 48(2): 337-341.
12.	Brahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene[J]. Biochem J, 1990, 268（2）: 287-294.
13.	Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15): 3412-3420.
14.	Finney H, Williams AH, Price CP. Serum cystatin C in patients with myeloma[J]. Clin Chim Acta, 2001, 309(1): 1-6.
15.	Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration[J]. Haematologica, 2009, 94(3): 372-379.
16.	Choi SJ, Reddy SV, Devlin RD, et al. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption[J]. J Biol Chem, 1999, 274(39): 27747-27753.

1. Abbott KC, Agodoal LY. Multiple myeloma and light chain associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival[J]. Clin Nephrol, 2001, 56(3): 207 -210.
2. Lamb EJ, Stowe HJ, Simpson DE, et al. Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful[J]. Clin Chem, 2004, 50(10): 1848-1851.
3. Heidtmann HH, Salge U, Abrahamson M, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines[J]. Clin Exp Metastasis, 1997, 15(4): 368-381.
4. Kos J, Stabuc B, Cimerman N, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression[J]. Clin Chem, 1998, 44(11): 2256-2257.
5. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays[J]. Oncogene, 2002, 21(44): 6848-6857.
6. 张之南, 沈悌. 血液病诊断及疗效标准[M]. 2版. 北京: 科学出版社，1998: 168-373.
7. Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int, 2004, 66(3): 1115-1122.
8. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: esults of a 4-year follow-up study[J]. J Am Soc Nephrol, 2005, 16(5):1404-1412.
9. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD[J]. Am J Kidney Dis, 2008, 51(3): 395-406.
10. Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma[J]. Bone Marrow Transplant，2007, 39(10): 605-611.
11. Eleutherakis-Papaiakovou V, Bamia A, Gika D, et al. Renal failure in multiple myeloma: incidence correlations, and prognostic significance[J]. Leuk Lymphoma, 2007, 48(2): 337-341.
12. Brahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene[J]. Biochem J, 1990, 268（2）: 287-294.
13. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15): 3412-3420.
14. Finney H, Williams AH, Price CP. Serum cystatin C in patients with myeloma[J]. Clin Chim Acta, 2001, 309(1): 1-6.
15. Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration[J]. Haematologica, 2009, 94(3): 372-379.
16. Choi SJ, Reddy SV, Devlin RD, et al. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption[J]. J Biol Chem, 1999, 274(39): 27747-27753.

West China Medical Journal

Clinical Significance of Cystatin-C in Patients with Multiple Myeloma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content